All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Arcutis Biotherapeutics has lined up another celeb to tout the benefits of its topical skin medicine Zoryve, adding ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...
Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
Just shy of two months after teeing up its FcRn blocker Vyvgart Hytrulo for entry into another potential immunology niche, ...
With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results